Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Abemaciclib
Drug: Abiraterone Acetate
Drug: Prednisolone

First Posted Date: 2019-08-28

Last Posted Date: 2021-09-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 6

Registration Number: NCT04071262

Locations: 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
Yokohama City University Medical Center, Yokohama, Kanagawa, Japan

A Study of LY3475766 in Healthy Participants

Phase 1

Completed

Conditions: Dyslipidemias

Interventions: Drug: LY3475766 - IV
Drug: Placebo - IV
Drug: LY3475766 - SC
Drug: Placebo - SC

First Posted Date: 2019-08-12

Last Posted Date: 2021-04-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 48

Registration Number: NCT04052594

Locations: 🇺🇸
WCCT Global, Cypress, California, United States
🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States
🇺🇸
Covance Dallas, Dallas, Texas, United States

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Hypoglycemia

Interventions: Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2019-08-08

Last Posted Date: 2024-05-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 42

Registration Number: NCT04050553

Locations: 🇦🇹
Universitätsklinikum Graz, Graz, Steiermark, Austria

A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tirzepatide

First Posted Date: 2019-08-08

Last Posted Date: 2023-05-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 54

Registration Number: NCT04050670

Locations: 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States

A Study of LY900014 in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY900014
Drug: Insulin Lispro

First Posted Date: 2019-08-07

Last Posted Date: 2021-11-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 15

Registration Number: NCT04049123

Locations: 🇨🇳
West China Hospital Sichuan University, Cheng Du, Cn-51, China

A Study of LY900020 in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY900020
Drug: Metformin XR
Drug: Atorvastatin
Drug: Valsartan

First Posted Date: 2019-08-07

Last Posted Date: 2020-03-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 32

Registration Number: NCT04047940

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Tirzepatide
Drug: Placebo

First Posted Date: 2019-07-31

Last Posted Date: 2022-01-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 475

Registration Number: NCT04039503

Locations: 🇩🇪
Schwerpunktpraxis Diabetes, Saint Ingbert-Oberwürzbach, Saarland, Germany
🇯🇵
Tokyo Center Clinic, Chuo-ku, Tokyo, Japan
🇺🇸
Sun Coast Clinical Research, Inc, New Port Richey, Florida, United States

and more 44 locations

A Study of LY3214996 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3214996
Drug: [14C]-LY3214996

First Posted Date: 2019-07-26

Last Posted Date: 2019-10-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 6

Registration Number: NCT04033341

Locations: 🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Phase 4

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Abemaciclib
Drug: Standard Chemotherapy
Drug: Fulvestrant

First Posted Date: 2019-07-24

Last Posted Date: 2021-08-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 4

Registration Number: NCT04031885

Locations: 🇺🇸
Yuma Regional Cancer Center, Yuma, Arizona, United States
🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸
Compassionate Cancer Care Medical Group Inc, Riverside, California, United States

and more 54 locations

A Study of LY3154885 in Healthy Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Placebo - Capsule
Drug: LY3154885 - Capsule
Drug: LY3154885 - Tablet
Drug: Itraconazole

First Posted Date: 2019-07-10

Last Posted Date: 2024-03-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT04014361

Locations: 🇺🇸
Covance, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy